A 3-year follow-up study after treatment with simeprevir in combination with pegylated interferon-α and ribavirin for chronic hepatitis C virus infection

Fabien Zoulim,Christophe Moreno,Samuel S. Lee,Peter Buggisch,Andrzej Horban,Eric Lawitz,Chris Corbett,Oliver Lenz,Bart Fevery,Thierry Verbinnen,Umesh Shukla,W. Jessner

A 3-year follow-up study after treatment with simeprevir in combination with pegylated interferon-α and ribavirin for chronic hepatitis C virus infection

2018

Fabien Zoulim
Christophe Moreno
Samuel S. Lee
Peter Buggisch
Andrzej Horban
Eric Lawitz
Chris Corbett
Oliver Lenz
Bart Fevery
Thierry Verbinnen
Umesh Shukla
W. Jessner

Background Simeprevir is approved with pegylated interferon and ribavirin (PR) for chronic hepatitis C virus (HCV) genotype (GT) 1 and GT4 infection in the USA and the European Union.

Keywords:

DIRECT ACTING ANTIVIRALS
Hepatitis C virus
Virology
Ribavirin
Pegylated interferon
Biology
Genotype
European union
Simeprevir
chronic hepatitis
Virus

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations